{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:24:46Z","timestamp":1790774686520,"version":"4.1.0"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.addr.2026.115863","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T13:08:27Z","timestamp":1775135307000},"page":"115863","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Reaching new heights? Maximum subcutaneous injection volumes from a technical and clinical development strategy perspective"],"prefix":"10.1016","volume":"234","author":[{"given":"Andrea","family":"Allmendinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanns-Christian","family":"Mahler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Bittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2026.115863_bb0005","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2402713","article-title":"Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products","volume":"16","author":"Green","year":"2024","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2026.115863_bb0010","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/1205121","article-title":"Factors affecting the absorption of subcutaneously administered insulin: effect on variability","volume":"2018","author":"Gradel","year":"2018","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.addr.2026.115863_bb0015","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.xphs.2018.01.007","article-title":"Challenges and opportunities for the subcutaneous delivery of therapeutic proteins","volume":"107","author":"Turner","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115863_bb0020","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/j.xphs.2016.05.029","article-title":"Subcutaneous injection volume of bio-pharmaceuticals-pushing the boundaries","volume":"105","author":"Mathaes","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115863_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.103914","article-title":"Development roadmap for subcutaneous delivery of high dose biologics - high concentration formula-tion, analytical comparability and patient preference considerations for large volume de-vices","volume":"114","author":"Ghosh","year":"2025","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115863_bb0030","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/ejhpharm-2022-003477","article-title":"Factors influencing the acceptability of different devices for subcutaneous drug delivery: a cross-sectional observational study from the patient's point of view","volume":"31","author":"Pivato","year":"2024","journal-title":"Eur. J. Hosp. Pharm."},{"key":"10.1016\/j.addr.2026.115863_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114156","article-title":"An industry perspective on clinical development and regulatory strategies for subcutaneously administered high-dose biologics","volume":"386","author":"Bruin","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115863_bb0040","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1080\/10717544.2019.1587043","article-title":"A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience","volume":"26","author":"van den Bemt","year":"2019","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2026.115863_bb0045","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-3148.2012.01201.x","article-title":"Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency","volume":"23","author":"Martin","year":"2013","journal-title":"Transfus. Med."},{"key":"10.1016\/j.addr.2026.115863_bb0050","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s40267-023-01038-5","article-title":"The PHASTER study: economic and organizational impact of subcutaneous (SC) Pertuzumab and Trastuzumab fixed-dose combination (pH FDC SC) for treatment of HER2+ breast cancer patients","volume":"39","author":"Munzone","year":"2023","journal-title":"Drugs Ther. Perspect."},{"key":"10.1016\/j.addr.2026.115863_bb0055","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1007\/s12325-024-02985-9","article-title":"Differences between intravenous and subcutaneous modes of administration in oncology from the patient, healthcare provider, and healthcare system perspectives: a systematic review","volume":"41","author":"R","year":"2024","journal-title":"Adv. Ther."},{"key":"10.1016\/j.addr.2026.115863_bb0060","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/14737167.2023.2249232","article-title":"Evaluation of the economic benefits, administration times, and patient preferences associated with the use of biotechnological drugs administered subcutaneously and intravenously in patients with cancer: a systematic review","volume":"23","author":"Parra","year":"2023","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"10.1016\/j.addr.2026.115863_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211783","article-title":"Economic benefits of subcutaneous trastuzumab administration: a single institutional study from Karolinska University Hospital in Sweden","volume":"14","author":"Hedayati","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2026.115863_bb0070","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities","volume":"32","author":"Bittner","year":"2018","journal-title":"BioDrugs"},{"key":"10.1016\/j.addr.2026.115863_bb0075","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2147\/JAA.S358738","article-title":"A. group, reliability, satisfaction and effectiveness of benralizumab home self-administration in patients with severe eosinophilic asthma in real-world practice: the auto-benra study","volume":"15","author":"Garcia-Moguel","year":"2022","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.addr.2026.115863_bb0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41120-022-00069-y","article-title":"Customer-centric product presentations for monoclonal antibodies","volume":"9","author":"Bittner","year":"2023","journal-title":"AAPS Open"},{"key":"10.1016\/j.addr.2026.115863_bb0085","series-title":"Drug Delivery Devices and Therapeutic Systems","first-page":"159","article-title":"Subcutaneous drug delivery devices: enablers of a flexible care setting","author":"Bittner","year":"2021"},{"key":"10.1016\/j.addr.2026.115863_bb0090","article-title":"Intravenous versus subcutaneous drug administration","volume":"Patient","author":"Stoner","year":"2014","journal-title":"Which Do Patients Prefer? A Systematic Rev."},{"key":"10.1016\/j.addr.2026.115863_bb0095","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2147\/PPA.S169339","article-title":"Patients' and nurses' preferences for autoinjectors for rheumatoid arthritis: results of a European survey","volume":"12","author":"Tischer","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.addr.2026.115863_bb0100","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40744-019-0144-8","article-title":"Nurse and patient perceptions and preferences for subcutaneous autoinjectors for inflammatory joint or bowel disease: findings from a European Survey","volume":"6","author":"Fenwick","year":"2019","journal-title":"Rheumatol. Ther."},{"key":"10.1016\/j.addr.2026.115863_bb0105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/PPA.S125137","article-title":"Subcutaneous sumatriptan delivery devices: comparative ease of use and preference among migraineurs","volume":"11","author":"Andre","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.addr.2026.115863_bb0110","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/17425247.2023.2219891","article-title":"Autoinjectors for large-volume subcutaneous drug delivery: a review of current research and future directions","volume":"20","author":"Schneider","year":"2023","journal-title":"Expert Opin. Drug. Deliv."},{"key":"10.1016\/j.addr.2026.115863_bb0115","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/17425247.2022.2162037","article-title":"Understanding patient preferences for handheld autoinjectors versus wearable large-volume injectors","volume":"20","author":"Schneider","year":"2023","journal-title":"Expert Opin. Drug. Deliv."},{"key":"10.1016\/j.addr.2026.115863_bb0120","first-page":"195","article-title":"Usability of devices for self-injection: results of a formative study on a new disposable pen injector","volume":"7","author":"Lange","year":"2014","journal-title":"Med. Devices (Auckl)"},{"key":"10.1016\/j.addr.2026.115863_bb0125","author":"Takeda. HYQVIA\u00ae (Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase) \u2013 Highlights of Prescribing Information"},{"key":"10.1016\/j.addr.2026.115863_bb0130","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2217\/imt-2022-0097","article-title":"Systemic IgG exposure and safety in patients with primary immunodeficiency: a randomized crossover study comparing a novel investigational wearable infusor versus the Crono pump","volume":"14","author":"Wasserman","year":"2022","journal-title":"Immunotherapy"},{"key":"10.1016\/j.addr.2026.115863_bb0135","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.3324\/haematol.2023.284730","article-title":"A multicenter, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"109","author":"Quach","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.addr.2026.115863_bb0140","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO-25-00744","article-title":"Isatuximab subcutaneous by on-body injector versus isatuximab intra-venous plus pomalidomide and dexamethasone in relapsed\/refractory multiple Myelo-ma: phase III IRAKLIA study","volume":"43","author":"Ailawadhi","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115863_bb0145","article-title":"Analytical control strategy for biologics","volume":"114","author":"Kendrick","year":"2025","journal-title":"Part I: Foundations, J Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115863_bb0150","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.biologicals.2016.07.004","article-title":"Introduction to the application of QbD principles for the development of monoclonal antibodies","volume":"44","author":"Finkler","year":"2016","journal-title":"Biologicals"},{"key":"10.1016\/j.addr.2026.115863_bb0155","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1208\/s12248-025-01132-8","article-title":"Insights from a survey of drug formulation experts: challenges and preferences in high-concentration subcutaneous biologic drug development","volume":"27","author":"Desai","year":"2025","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2026.115863_bb0160","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1016\/j.xphs.2019.02.027","article-title":"A novel pharmacokinetic bridging strategy to support a change in the route of administration for biologics","volume":"108","author":"Ji","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115863_bb0165","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of monoclonal antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.addr.2026.115863_bb0170","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1124\/dmd.114.059238","article-title":"Subcutaneous absorption of biotherapeutics: knowns and unknowns","volume":"42","author":"Richter","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.addr.2026.115863_bb0175","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.xphs.2023.11.004","article-title":"Roadmap for drug product development and manufacturing of biologics","volume":"113","author":"Sampathkumar","year":"2024","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115863_bb0180","first-page":"44","article-title":"Integrated drug product development and manufacturing","volume":"147","author":"Allmendinger","year":"2023","journal-title":"ONdrugDelivery"},{"key":"10.1016\/j.addr.2026.115863_bb0185","first-page":"14","article-title":"Technical challenges during the development of on-body injectors","volume":"Issue 164","author":"Allmendinger","year":"2024","journal-title":"ONdrugDelivery"},{"key":"10.1016\/j.addr.2026.115863_bb0190","author":"BioPhorum Operations Group. Platforms for regulatory CMC: the necessary definitions"},{"key":"10.1016\/j.addr.2026.115863_bb0195","first-page":"8","article-title":"Transitioning from vial to subcutaneous injection devices for biological drug products","volume":"160","author":"Adler","year":"2024","journal-title":"ONdrugDelivery"},{"key":"10.1016\/j.addr.2026.115863_bb0200","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1007\/s13555-022-00789-9","article-title":"High tolerability, favorable safety, and subjects' preference for a single 200\u00a0mg\/2\u00a0mL Tildrakizumab Injection: a phase I, open-label, randomized crossover trial in healthy volunteers","volume":"12","author":"Kokolakis","year":"2022","journal-title":"Dermatol. Ther. (Heidelb.)"},{"key":"10.1016\/j.addr.2026.115863_bb0205","author":"European Medicines Agency. Bimzelx: European public assessment report. Amsterdam: EMA"},{"key":"10.1016\/j.addr.2026.115863_bb0210","series-title":"Skyrizi (risankizumab-rzaa): Highlights of Prescribing Information","author":"AbbVie Inc","year":"2019"},{"key":"10.1016\/j.addr.2026.115863_bb0215","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/DDDT.S287323","article-title":"Subcutaneous delivery of high-dose\/volume biologics: current status and prospect for future advancements","volume":"15","author":"Badkar","year":"2021","journal-title":"Drug. Des. Devel. Ther."},{"key":"10.1016\/j.addr.2026.115863_bb0220","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.xphs.2025.01.028","article-title":"Developing ultra-high concentration formulations of human immune globulins for subcutaneous injectables","volume":"114","author":"Yadav","year":"2025","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115863_bb0225","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adv6427","article-title":"Ultrahigh-concentration biologic therapeutics enabled by spray drying with a glassy surfactant excipient","volume":"17","author":"Jons","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2026.115863_bb0230","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/jps.20079","article-title":"Challenges in the development of high protein concentration formulations","volume":"93","author":"Shire","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115863_bb0235","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2550757","article-title":"Mechanistic and predictive formulation develop-ment for viscosity mitigation of high-concentration biotherapeutics","volume":"17","author":"Cruz","year":"2025","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2026.115863_bb0240","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1021\/acs.molpharmaceut.5b00937","article-title":"Pharmaceutical perspective on opalescence and liquid-liquid phase separation in protein solutions","volume":"13","author":"Raut","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115863_bb0245","series-title":"Protein Therapeutics. Methods and Principles in Medicinal Chemistry, Part IV","first-page":"469","article-title":"Stability, formulation, and delivery of biopharmaceuticals","volume":"2","author":"Mahler","year":"2017"},{"key":"10.1016\/j.addr.2026.115863_bb0250","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ejpb.2014.01.009","article-title":"Rheological characterization and injection forces of concentrated protein formulations: an alternative predictive model for non-Newtonian solutions","volume":"87","author":"Allmendinger","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2026.115863_bb0255","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s11095-024-03726-x","article-title":"Stability of protein pharmaceuticals: recent advances","volume":"41","author":"MC","year":"2024","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115863_bb0260","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1517\/17425247.4.4.427","article-title":"Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration","volume":"4","author":"Frost","year":"2007","journal-title":"Expert Opin. Drug. Deliv."},{"key":"10.1016\/j.addr.2026.115863_bb0265","series-title":"MabThera 1400\u00a0mg: Summary of Product Characteristics","author":"AG","year":"2014"},{"key":"10.1016\/j.addr.2026.115863_bb0270","author":"Genentech Inc"},{"key":"10.1016\/j.addr.2026.115863_bb0275","author":"Genentech Inc"},{"key":"10.1016\/j.addr.2026.115863_bb0280","author":"AG"},{"key":"10.1016\/j.addr.2026.115863_bb0285","author":"Genentech Inc"},{"key":"10.1016\/j.addr.2026.115863_bb0290","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.1016\/j.vaccine.2007.04.062","article-title":"Brighton collaboration local reactions working group for induration at or near injection, induration at or near injection site: case defini-tion and guidelines for collection, analysis, and presentation of immunization safety data","volume":"25","author":"Kohl","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2026.115863_bb0295","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s11095-024-03683-5","article-title":"Clinical investigation of large volume subcutaneous delivery up to 25\u00a0mL for Lean and non-lean subjects","volume":"41","author":"Dang","year":"2024","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115863_bb0300","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/jphp.12731","article-title":"Challenges for the pharmaceutical technical development of protein coformulations","volume":"70","author":"Mueller","year":"2018","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2026.115863_bb0305","unstructured":"Halozyme Inc. Enhanze\u00ae. San Diego, CA: Halozyme Inc. Retrieved October 8, 2025 https:\/\/halozyme.com\/drug-delivery-technologies\/enhanze\/."},{"key":"10.1016\/j.addr.2026.115863_bb0310","unstructured":"Bao Pharma. Hysorptase\u00ae Recombinant Human Hyaluronidase. Retrieved October 4, 2025 https:\/\/www.baopharma.com\/Science\/1."},{"key":"10.1016\/j.addr.2026.115863_bb0315","author":"Alteogen Inc. Tergase\u00ae: Novel Recombinant Human Hyaluronidase"},{"key":"10.1016\/j.addr.2026.115863_bb0320","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jconrel.2023.06.034","article-title":"Drug delivery breakthrough technologies - a perspective on clinical and societal impact","volume":"360","author":"Bittner","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115863_bb0325","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1021\/acsptsci.3c00377","article-title":"Disease-agnostic electronic adherence aid for subcutaneous at-home and self-administration devices-the lowest common denominator based on a cross-indication survey","volume":"7","author":"Bittner","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.addr.2026.115863_bb0330","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2147\/PPA.S203775","article-title":"From drug-delivery device to disease management tool: a study of preferences for enhanced features in next-generation self-injection devices","volume":"13","author":"Boeri","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.addr.2026.115863_bb0335","first-page":"101","article-title":"Connected drug delivery devices to complement drug treatments: potential to facilitate disease management in home setting","volume":"12","author":"Bittner","year":"2019","journal-title":"Med. Devices (Auckl)"},{"key":"10.1016\/j.addr.2026.115863_bb0340","series-title":"Combination Products for Biotech Injectables","article-title":"The new paradigm\u2014customer-centric, sustainable product design","author":"Allmendinger","year":"2025"},{"key":"10.1016\/j.addr.2026.115863_bb0345","unstructured":"A. Allmendinger, S. Fischer. Antibody formulation. Patent WO\/2025\/056655."},{"key":"10.1016\/j.addr.2026.115863_bb0350","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s11095-020-02906-9","article-title":"Tissue resistance during large-volume injections in subcutaneous tissue of minipigs","volume":"37","author":"Allmendinger","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115863_bb0355","series-title":"Challenges in Protein Product Development. AAPS Advances in the Pharmaceutical Sciences Series","article-title":"Practical considerations for high concentration protein formulations","volume":"38","author":"Piedmonte","year":"2018"},{"key":"10.1016\/j.addr.2026.115863_bb0360","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ddtec.2020.08.005","article-title":"Development challenges of high concentration monoclonal antibody formulations","volume":"37","author":"Kollar","year":"2020","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.addr.2026.115863_bb0365","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.xphs.2021.11.008","article-title":"Ongoing challenges to develop high concentration monoclonal antibody-based formulations for subcutaneous administration: quo vadis?","volume":"111","author":"Jiskoot","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115863_bb0370","article-title":"Polysorbates degrading enzymes in biotherapeutics - a current status and future perspectives","volume":"12","author":"Felix","year":"2024","journal-title":"Front Bioeng Biotechnol."},{"key":"10.1016\/j.addr.2026.115863_bb0375","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1021\/acs.molpharmaceut.5b00311","article-title":"Polysorbate 20 degradation in biopharmaceutical formulations: quantification of free fatty acids, characterization of particulates, and insights into the degradation mechanism","volume":"12","author":"Tomlinson","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115863_bb0380","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ijpharm.2018.10.008","article-title":"Polysorbate degradation in biotherapeutic formulations: identification and discussion of current root causes","volume":"552","author":"Dwivedi","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115863_bb0385","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1016\/j.xphs.2018.07.016","article-title":"Are injection site reactions in monoclonal antibody therapies caused by polysorbate excipient degradants?","volume":"107","author":"Singh","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115863_bb0390","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2285277","article-title":"Monoclonal antibody and protein therapeutic formulations for subcutaneous delivery: high-concentration, low-volume vs. low-concentration, high-volume","volume":"15","author":"Desai","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2026.115863_bb0395","author":"U.S. Food and Drug Administration. Allowable Excess Volume and Labeled Vial Fill Size in Injectable Drug and Biological Products \u2013 Guidance for Industry. Silver Spring, MD: U.S. Food and Drug Administration"},{"key":"10.1016\/j.addr.2026.115863_bb0400","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/cpt.875","article-title":"Dose rationalization of Pembrolizumab and Nivolumab using pharmacokinetic modeling and simulation and cost analysis","volume":"103","author":"Ogungbenro","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2026.115863_bb0405","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.xphs.2021.09.043","article-title":"An intercompany perspective on compatibility and in-use stability studies to enable administration of biopharmaceutical drug products","volume":"111","author":"Kamen","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115863_bb0410","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4103\/2230-973X.93004","article-title":"Prefilled syringes: an innovation in parenteral packaging","volume":"1","author":"Makwana","year":"2011","journal-title":"Int. J. Pharm. Investig."},{"key":"10.1016\/j.addr.2026.115863_bb0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10837450.2014.982825","article-title":"Pre-filled syringes: a review of the history, manufac-turing and challenges","volume":"20","author":"Sacha","year":"2015","journal-title":"Pharm. Dev. Technol."},{"issue":"6","key":"10.1016\/j.addr.2026.115863_bb0420","article-title":"Implementation of a platform approach for early biologics development","volume":"14","author":"Siedler","year":"2011","journal-title":"American Pharmaceutical Rev"},{"key":"10.1016\/j.addr.2026.115863_bb0425","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1002\/jps.20976","article-title":"Antimicrobial preservative use in parenteral products: past and present","volume":"96","author":"Meyer","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115863_bb0430","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15020563","article-title":"Antimicrobial preservatives for protein and peptide formulations: an overview","volume":"15","author":"Stroppel","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115863_bb0435","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1007\/s11095-015-1697-z","article-title":"Interactions between peptide and preservatives: effects on peptide self-interactions and antimicrobial efficiency in aqueous multi-dose formulations","volume":"32","author":"Heljo","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115863_bb0440","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/j.xphs.2016.04.009","article-title":"Understanding subcutaneous tissue pressure for engineering injection devices for large-volume protein delivery","volume":"105","author":"Doughty","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115863_bb0445","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1177\/1932296815626723","article-title":"Injection technique and pen needle design affect leakage from skin after subcutaneous injections","volume":"10","author":"Praestmark","year":"2016","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2026.115863_bb0450","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1007\/s11095-014-1611-0","article-title":"Measuring tissue back-pressure\u2013in vivo injection forces during subcutaneous injection","volume":"32","author":"Allmendinger","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115863_bb0455","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1208\/s12249-020-01880-0","article-title":"Subcutaneous injection performance in yucatan miniature pigs with and without human hyaluronidase and auto-injector tolerability in humans","volume":"22","author":"Shi","year":"2021","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.addr.2026.115863_bb0460","first-page":"406","article-title":"Subcutaneous administration of bortezomib: strate-gies to reduce injection site reactions","volume":"3","author":"Kurtin","year":"2012","journal-title":"J. Adv. Pract. Oncol."},{"key":"10.1016\/j.addr.2026.115863_bb0465","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1185\/03007995.2010.481203","article-title":"Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations","volume":"26","author":"Gibney","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.addr.2026.115863_bb0470","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1089\/dia.2014.0111","article-title":"Intramuscular risk at insulin injection sites\u2013measurement of the distance from skin to muscle and rationale for shorter-length needles for subcutaneous insulin therapy","volume":"16","author":"Hirsch","year":"2014","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2026.115863_bb0475","doi-asserted-by":"crossref","first-page":"606","DOI":"10.5414\/CP203023","article-title":"Tralokinumab pharmacokinetics and tolerability when administered by different subcutaneous injection methods and rates","volume":"55","author":"Jain","year":"2017","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2026.115863_bb0480","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.clinthera.2019.11.015","article-title":"A phase i study to assess the effect of speed of injection on pain, tolerability, and pharmacokinetics after high-volume subcutaneous administration of gantenerumab in healthy volunteers","volume":"42","author":"Portron","year":"2020","journal-title":"Clin. Ther."},{"key":"10.1016\/j.addr.2026.115863_bb0485","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/dom.12304","article-title":"Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial","volume":"16","author":"Heise","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.addr.2026.115863_bb0490","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1932296817735121","article-title":"Impact of injection speed, vol-ume, and site on pain sensation","volume":"12","author":"Zijlstra","year":"2018","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2026.115863_bb0495","first-page":"473","article-title":"Evaluation of the impact of viscosity, injection volume, and injection flow rate on subcutaneous injection tolerance","volume":"8","author":"Berteau","year":"2015","journal-title":"Med. Devices (Auckl)"},{"key":"10.1016\/j.addr.2026.115863_bb0500","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1177\/193229680700100517","article-title":"Does needle size matter?","volume":"1","author":"Gill","year":"2007","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2026.115863_bb0505","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.otc.2020.05.014","article-title":"Nonenteral pain management","volume":"53","author":"Tinkey","year":"2020","journal-title":"Otolaryngol. Clin. N. Am."},{"key":"10.1016\/j.addr.2026.115863_bb0510","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.clinthera.2004.10.007","article-title":"A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge\u00a0\u00d7\u00a06\u00a0mm needle versus a 29 gauge\u00a0\u00d7\u00a012.7\u00a0mm needle in obese patients with diabetes mellitus","volume":"26","author":"Schwartz","year":"2004","journal-title":"Clin. Ther."},{"key":"10.1016\/j.addr.2026.115863_bb0515","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/08990220600700925","article-title":"Pain following controlled cutaneous inser-tion of needles with different diameters","volume":"23","author":"Arendt-Nielsen","year":"2006","journal-title":"Somatosens. Mot. Res."},{"key":"10.1016\/j.addr.2026.115863_bb0520","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.xphs.2016.09.034","article-title":"If Euhydric and Iso-tonic do not work, what are acceptable ph and osmolality for parenteral drug dosage forms?","volume":"106","author":"Roethlisberger","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115863_bb0525","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s40744-020-00245-0","article-title":"Understanding and minimizing injection-site pain following subcutaneous administration of biologics: a narrative review","volume":"7","author":"St Clair-Jones","year":"2020","journal-title":"Rheumatol. Ther."},{"key":"10.1016\/j.addr.2026.115863_bb0530","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/cts.13109","article-title":"Clinical evaluation of large volume subcutaneous injection tissue effects, pain, and acceptability in healthy adults","volume":"15","author":"Woodley","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.addr.2026.115863_bb0535","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1007\/s12325-019-01101-6","article-title":"Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site","volume":"36","author":"Usach","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.addr.2026.115863_bb0540","article-title":"Alternative routes of administration for ther-apeutic antibodies-state of the art","volume":"11","author":"Pitiot","year":"2022","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.addr.2026.115863_bb0545","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.addr.2026.115863_bb0550","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1200\/JCO.2003.10.084","article-title":"Horseshoes, hand grenades, and body-surface area-based dosing: aiming for a target","volume":"21","author":"Egorin","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115863_bb0555","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40425-017-0242-5","article-title":"Evaluation of dosing strategy for pembrolizumab for oncology indications","volume":"5","author":"Freshwater","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.addr.2026.115863_bb0560","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/cas.14252","article-title":"Benefit-risk assessment of nivolumab 240\u00a0mg flat dose relative to 3\u00a0mg\/kg Q2W regimen in Japanese patients with advanced cancers","volume":"111","author":"Bei","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.addr.2026.115863_bb0565","series-title":"Formulation and Device Lifecycle Management of Biotherapeutics: A Guidance for Researchers and Drug Developers","author":"B","year":"2022"},{"key":"10.1016\/j.addr.2026.115863_bb0570","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40259-023-00626-1","article-title":"Advancing subcutaneous dosing regimens for biotherapeutics: clinical strategies for expedited market access","volume":"38","author":"Bittner","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.addr.2026.115863_bb0575","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4161\/mabs.4.1.18543","article-title":"Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice","volume":"4","author":"Deng","year":"2012","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2026.115863_bb0580","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4161\/mabs.4.2.19364","article-title":"Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys","volume":"4","author":"Datta-Mannan","year":"2012","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2026.115863_bb0585","article-title":"A physiologically based pharmacokinetic model relates the subcutaneous bioavailability of monoclonal antibodies to the saturation of FcRn-mediated recycling in injection-site-draining lymph nodes","volume":"13","author":"Stader","year":"2024","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.addr.2026.115863_bb0590","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/19420862.2015.1128606","article-title":"Molecular basis of high viscosity in concentrated antibody solutions: strategies for high concentration drug product development","volume":"8","author":"Tomar","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2026.115863_bb0595","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.iac.2008.06.005","article-title":"Self-infusion programmes for immunoglobulin replacement at home: feasibility, safety and efficacy","volume":"28","author":"Bhole","year":"2008","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"10.1016\/j.addr.2026.115863_bb0600","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.clim.2011.06.002","article-title":"Efficacy and safety of Hizentra((R)) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy","volume":"141","author":"Jolles","year":"2011","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.addr.2026.115863_bb0605","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/pai.12026","article-title":"Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics","volume":"24","author":"Shapiro","year":"2013","journal-title":"Pediatr. Allergy Immunol."},{"key":"10.1016\/j.addr.2026.115863_bb0610","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s10875-023-01632-2","article-title":"A Phase 1 open-label study to assess the tolerability, safety, and immunogenicity of hyaluronidase-facilitated subcutaneous immunoglobulin 20% in healthy adults","volume":"44","author":"Nagy","year":"2023","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.addr.2026.115863_bb0615","series-title":"Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases \u2013 Guidance for Industry","author":"Food","year":"2024"},{"key":"10.1016\/j.addr.2026.115863_bb0620","series-title":"ICH Q5E: Comparability of Biotechnological\/Biological Products Subject to Changes in Their Manufacturing Process (Step 5, CPMP\/ICH\/5721\/03)","author":"European Medicines Agency","year":"2005"},{"key":"10.1016\/j.addr.2026.115863_bb0625","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1080\/14712598.2022.2113053","article-title":"A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)","volume":"22","author":"Patel","year":"2022","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.addr.2026.115863_bb0630","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1208\/s12248-020-0433-8","article-title":"Systematic review of device parameters and design of studies bridging biologic-device combination products using prefilled syringes and autoinjectors","volume":"22","author":"Hu","year":"2020","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2026.115863_bb0635","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.clinthera.2023.10.008","article-title":"Clinical bridging from prefilled syringe to on-body injector for Risankizumab in Crohn's disease","volume":"46","author":"Pang","year":"2024","journal-title":"Clin. Ther."},{"key":"10.1016\/j.addr.2026.115863_bb0640","series-title":"Reflection paper on a tailored clinical approach in biosimilar development. EMA\/CHMP\/BMWP\/60916\/2025","author":"European Medicines Agency","year":"2025"},{"key":"10.1016\/j.addr.2026.115863_bb0645","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.24.01001","article-title":"Subcutaneous versus intravenous amivantamab, both in combination with Lazertinib, in refractory epidermal growth factor receptor-mutated non-small cell lung cancer: primary results from the phase III PALOMA-3 study","volume":"42","author":"Leighl","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115863_bb0650","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/blood.2019000667","article-title":"Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma","volume":"134","author":"Usmani","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.addr.2026.115863_bb0655","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40259-025-00755-9","article-title":"Clinical qualification of subcutaneous injection devices for monoclonal antibodies","volume":"40","author":"Bittner","year":"2026","journal-title":"BioDrugs"},{"key":"10.1016\/j.addr.2026.115863_bb0660","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/jcph.4","article-title":"The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model","volume":"53","author":"Zhao","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2026.115863_bb0665","author":"Amgen Inc. REPATHA\u00ae (evolocumab) \u2013 Highlights of Prescribing Information"},{"key":"10.1016\/j.addr.2026.115863_bb0670","author":"Amgen Inc. Repatha\u00ae Pushtronex\u00ae System (on-body infusor with prefilled cartridge) Discontinuation"},{"key":"10.1016\/j.addr.2026.115863_bb0675","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/cei.12694","article-title":"Facilitated subcutaneous immunoglobulin (fSCIg) therapy\u2013practical considerations","volume":"182","author":"Ponsford","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.addr.2026.115863_bb0680","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s10875-024-01742-5","article-title":"Tolerability and safety of large-volume hyaluronidase-facilitated subcutaneous immunoglobulin 10% administered with or without dose ramp-up: a phase 1 study in healthy participants","volume":"44","author":"Li","year":"2024","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.addr.2026.115863_bb0685","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2147\/PPA.S502444","article-title":"Patient preferences for faster home-based subcutaneous immunoglobulin infusion therapy and the effect on adverse events","volume":"19","author":"Rutland","year":"2025","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.addr.2026.115863_bb0690","article-title":"The reliability of auto-injectors in clinical use: a systematic review","volume":"15","author":"Dostal","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.addr.2026.115863_bb0695","series-title":"Protein therapeutics market analysis & forecast","first-page":"2025","author":"Insights","year":"2025"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26000979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26000979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T03:38:17Z","timestamp":1779075497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X26000979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":139,"alternative-id":["S0169409X26000979"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2026.115863","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reaching new heights? Maximum subcutaneous injection volumes from a technical and clinical development strategy perspective","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2026.115863","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115863"}}